Journal of Neuro-Oncology

, Volume 94, Issue 2, pp 169–172

No association of (−131C→G) variant of CHI3L1 gene with risk of glioblastoma and prognosis

  • Blandine Boisselier
  • Yannick Marie
  • Soufiane El Hallani
  • Gentian Kaloshi
  • Anton Iershov
  • Vadym Kavsan
  • Dimitri Psimaras
  • Joëlle Thillet
  • Khe Hoang-Xuan
  • Jean-Yves Delattre
  • Marc Sanson
Laboratory Investigations - Human/Animal Tissue
  • 115 Downloads

Abstract

Expression of CHI3L1 (YKL-40) has been correlated with prognosis of glioblastoma. The variant allele (−131C→G) of CHI3L1 promoter results in a lower transcription of CHI3L1. Therefore, we tested the hypothesis that the G variant could protect against the risk of gliomas or have a favorable prognostic impact. DNA from 296 glioblastoma patients and 190 controls were genotyped on the −131 allele. Tumor RNA was obtained from 108 patients for CHI3L1 transcript quantification. Neither genotype nor allele distribution differed between patients and controls. There was no significant difference in survival between the CC, CG, and GG patients despite the few GG patients tended to have a longer survival. There was no correlation between genotype and CHI3L1 expression in tumor samples. Taken together our data suggest that the variant allele (−131C→G) of CHI3L1 promoter has no significant impact on survival and is not a prognostic factor for glioblastoma.

Keywords

Glioblastoma CHI3L1 Polymorphism Prognosis 

References

  1. 1.
    Johansen JS (2006) Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53:172–209PubMedGoogle Scholar
  2. 2.
    Tanwar MK, Gilbert MR, Holland EC (2002) Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 62:4364–4368PubMedGoogle Scholar
  3. 3.
    Shostak K, Labunskyy V, Dmitrenko V, Malisheva T, Shamayev M, Rozumenko V, Zozulya Y, Zehetner G, Kavsan V (2003) HC gp-39 gene is upregulated in glioblastomas. Cancer Lett 198:203–210. doi:10.1016/S0304-3835(03)00310-0 PubMedCrossRefGoogle Scholar
  4. 4.
    Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN, Stemmer-Rachamimov AO (2005) YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res 11:2258–2264. doi:10.1158/1078-0432.CCR-04-1601 PubMedCrossRefGoogle Scholar
  5. 5.
    Junker N, Johansen JS, Hansen LT, Lund EL, Kristjansen PE (2005) Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci 96:183–190. doi:10.1111/j.1349-7006.2005.00026.x PubMedCrossRefGoogle Scholar
  6. 6.
    Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ (1999) Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 250:168–173. doi:10.1006/excr.1999.4511 PubMedCrossRefGoogle Scholar
  7. 7.
    Nishikawa KC, Millis AJ (2003) gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 287:79–87. doi:10.1016/S0014-4827(03)00069-7 PubMedCrossRefGoogle Scholar
  8. 8.
    Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC (2006) YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 12:5698–5704. doi:10.1158/1078-0432.CCR-06-0181 PubMedCrossRefGoogle Scholar
  9. 9.
    Zhao X, Tang R, Gao B, Shi Y, Zhou J, Guo S, Zhang J, Wang Y, Tang W, Meng J, Li S, Wang H, Ma G, Lin C, Xiao Y, Feng G, Lin Z, Zhu S, Xing Y, Sang H, St Clair D, He L (2007) Functional variants in the promoter region of Chitinase 3-like 1 (CHI3L1) and susceptibility to schizophrenia. Am J Hum Genet 80:12–18. doi:10.1086/510438 PubMedCrossRefGoogle Scholar
  10. 10.
    Ober C, Tan Z, Sun Y, Possick JD, Pan L, Nicolae R, Radford S, Parry RR, Heinzmann A, Deichmann KA, Lester LA, Gern JE, Lemanske RF Jr, Nicolae DL, Elias JA, Chupp GL (2008) Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med 358:1682–1691. doi:10.1056/NEJMoa0708801 PubMedCrossRefGoogle Scholar
  11. 11.
    Stupp R, van den Bent MW, Weller MJ, Fisher M, Taphoorn B, Belanger MJ, Brandes K, Marosi AA, Bogdahn C, Curschmann U, Janzer J, Ludwin RC, Gorlia SK, Allgeier T, Lacombe A, Cairncross D, Eisenhauer JG, Mirimanoff E, R. O. European Organisation for Research, Treatment of Cancer Brain Tumor, Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. doi:10.1056/NEJMoa043330 PubMedCrossRefGoogle Scholar
  12. 12.
    Schwartzbaum J, Jonsson F, Ahlbom A, Preston-Martin S, Lönn S, Söderberg KC, Feychting M (2003) Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk. Int J Cancer 106:423–428. doi:10.1002/ijc.11230 PubMedCrossRefGoogle Scholar
  13. 13.
    Wiemels JL, Wiencke JK, Patoka J, Moghadassi M, Chew T, McMillan A, Miike R, Barger G, Wrensch M (2004) Reduced immunoglobulin E and allergy among adults with glioma compared with controls. Cancer Res 64:8468–8473. doi:10.1158/0008-5472.CAN-04-1706 PubMedCrossRefGoogle Scholar
  14. 14.
    Wrensch M, Wiencke JK, Wiemels J, Miike R, Patoka J, Moghadassi M, McMillan A, Kelsey KT, Aldape K, Lamborn KR, Parsa AT, Sison JD, Prados MD (2006) Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res 66:4531–4541. doi:10.1158/0008-5472.CAN-05-4032 PubMedCrossRefGoogle Scholar
  15. 15.
    Schwartzbaum J, Ahlbom A, Malmer B, Lönn S, Brookes AJ, Doss H, Debinski W, Henriksson R, Feychting M (2005) Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res 65:6459–6465. doi:10.1158/0008-5472.CAN-04-3728 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Blandine Boisselier
    • 1
    • 2
  • Yannick Marie
    • 1
    • 2
  • Soufiane El Hallani
    • 1
    • 2
  • Gentian Kaloshi
    • 3
  • Anton Iershov
    • 1
    • 4
  • Vadym Kavsan
    • 4
  • Dimitri Psimaras
    • 3
  • Joëlle Thillet
    • 1
    • 2
  • Khe Hoang-Xuan
    • 1
    • 2
    • 3
  • Jean-Yves Delattre
    • 1
    • 2
    • 3
  • Marc Sanson
    • 1
    • 2
    • 3
  1. 1.INSERM, U711, Biologie des Interactions Neurones & GlieParisFrance
  2. 2.Faculté de MédecineUniversité Pierre et Marie CurieParisFrance
  3. 3.Service de Neurologie MazarinGroupe Hospitalier Pitié-SalpêtrièreParisFrance
  4. 4.Institute of Molecular Biology and GeneticsNASUKievUkraine

Personalised recommendations